STOCK TITAN

Arrowhead (ARWR) Insider Files Form 144 to Sell 15,000 Shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Arrowhead Research (ARWR) Form 144 notice: An individual identified as James Hamilton plans to sell 15,000 common shares through Merrill Lynch on 09/02/2025 with an aggregate market value of $374,970.05. The filing shows 138,257,550 shares outstanding for the issuer and names NASDAQ as the exchange.

The filing discloses the acquisition history for the shares being sold: multiple compensation grants between 01/04/2022 and 01/04/2025 totaling the reported units, and prior sales in August 2025 of 611 and 9,389 shares generating gross proceeds of $12,190.05 and $187,750.05, respectively. The filer affirms no undisclosed material adverse information.

Positive

  • Disclosure compliance: Form 144 provides required details including broker, exchange, acquisition dates, and prior sales
  • Clear acquisition history: All listed shares were acquired as compensation with specific dates from 2022 through 2025
  • Prior sales reported: August 2025 sales of 611 and 9,389 shares with gross proceeds are disclosed

Negative

  • Insider selling activity: Proposed sale of 15,000 shares may be viewed negatively by some investors
  • Concentration of sales by one person: Multiple compensation grants and clustered disposals could raise liquidity questions for that insider

Insights

TL;DR: Routine insider sale notice showing small-volume dispositions filed under Rule 144; transparency maintained.

The Form 144 discloses a proposed sale of 15,000 common shares with clear acquisition dates and compensation as the source. Broker and exchange are identified, and recent August sales are reported with gross proceeds. This is a standard compliance filing that notifies the market of intended restricted/affiliate sales; the disclosed figures allow investors to quantify the transaction but do not by themselves indicate company performance.

TL;DR: Filing meets disclosure requirements for insider sales and includes representation about material non-public information.

The notice properly lists the person for whose account the securities will be sold, the acquisition history showing compensation grants across multiple years, and recent sales during the past three months. The signature representation about lack of material non-public information is included. From a governance perspective, this is a routine disclosure ensuring market transparency regarding insider liquidity.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the ARWR Form 144 disclose about the proposed sale?

The notice discloses a proposed sale of 15,000 common shares through Merrill Lynch on 09/02/2025 with an aggregate market value of $374,970.05 on NASDAQ.

Who is the person selling the shares on the Form 144?

The filing shows sales and acquisitions attributed to James Hamilton, including recent August 2025 dispositions and multiple compensation grants.

What prior sales in the past three months are reported for ARWR?

The Form 144 reports sales on 08/13/2025 of 611 shares (gross proceeds $12,190.05) and on 08/15/2025 of 9,389 shares (gross proceeds $187,750.05).

How were the shares that are being sold originally acquired?

All listed lots were acquired as compensation on dates between 01/04/2022 and 01/04/2025 as shown in the filing.

Which broker and exchange are being used for the proposed sale?

The broker is listed as Merrill Lynch (75 Rockefeller Plz, New York) and the exchange is NASDAQ.
Arrowhead Pharma

NASDAQ:ARWR

ARWR Rankings

ARWR Latest News

ARWR Latest SEC Filings

ARWR Stock Data

9.70B
131.61M
4.43%
77.49%
9.21%
Biotechnology
Pharmaceutical Preparations
Link
United States
PASADENA